 | |
| Clinical data | |
|---|---|
| Trade names | Meptid |
| AHFS/Drugs.com | International Drug Names |
| Dependence liability | Low |
| Routes of administration | By mouth,intramuscular,intravenous |
| Drug class | Opioid |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours |
| Eliminationhalf-life | Half-life (1.4–4 hours) |
| Excretion | The drug is rapidly metabolized to theglucuronide, and mostly excreted in the urine |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.053.718 |
| Chemical and physical data | |
| Formula | C15H23NO |
| Molar mass | 233.355 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Meptazinol, sold under the brand nameMeptid, is anopioidanalgesic developed byWyeth in the 1970s.[1] Indications for use in moderate to severepain, most commonly used to treat pain inobstetrics (childbirth).
Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes likeethoheptazine andproheptazine are4-phenylazepanes.
A partialμ-opioid receptoragonist, its mixedagonist/antagonist activity affords it a lower risk ofdependence andabuse than full μagonists likemorphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to otheropioids such asmorphine,pentazocine, orbuprenorphine.[2]
